News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
742,644 Results
Type
Article (43885)
Company Profile (318)
Press Release (698427)
Multimedia
Podcasts (116)
Webinars (19)
Section
Business (211055)
Career Advice (2114)
Deals (36769)
Drug Delivery (124)
Drug Development (83443)
Employer Resources (176)
FDA (16839)
Job Trends (15508)
News (357490)
Policy (34148)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2618)
Accelerated approval (34)
Adcomms (26)
Allergies (150)
Alliances (51605)
ALS (174)
Alzheimer's disease (1699)
Antibody-drug conjugate (ADC) (327)
Approvals (17105)
Artificial intelligence (543)
Autoimmune disease (162)
Automation (42)
Bankruptcy (372)
Best Places to Work (11775)
BIOSECURE Act (21)
Biosimilars (198)
Biotechnology (188)
Bladder cancer (161)
Brain cancer (61)
Breast cancer (655)
Cancer (4937)
Cardiovascular disease (422)
Career advice (1792)
Career pathing (37)
CAR-T (287)
CDC (49)
Celiac Disease (2)
Cell therapy (763)
Cervical cancer (36)
Clinical research (71223)
Collaboration (1777)
Company closure (4)
Compensation (1181)
Complete response letters (65)
COVID-19 (2790)
CRISPR (99)
C-suite (890)
Cystic fibrosis (148)
Data (6337)
Decentralized trials (2)
Denatured (36)
Depression (138)
Diabetes (510)
Diagnostics (6797)
Digital health (49)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (263)
Drug pricing (202)
Drug shortages (31)
Duchenne muscular dystrophy (235)
Earnings (91994)
Editorial (61)
Employer branding (21)
Employer resources (155)
Events (120385)
Executive appointments (1009)
FDA (20023)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (11)
Frontotemporal dementia (23)
Funding (1499)
Gene editing (206)
Generative AI (46)
Gene therapy (617)
GLP-1 (1017)
Government (4811)
Grass and pollen (7)
Guidances (385)
Healthcare (19076)
HIV (62)
Huntington's disease (46)
IgA nephropathy (86)
Immunology and inflammation (268)
Immuno-oncology (61)
Indications (119)
Infectious disease (3067)
Inflammatory bowel disease (201)
Inflation Reduction Act (14)
Influenza (119)
Intellectual property (259)
Interviews (328)
IPO (16924)
IRA (57)
Job creations (4070)
Job search strategy (1501)
JPM (64)
Kidney cancer (16)
Labor market (86)
Layoffs (576)
Leadership (34)
Legal (8430)
Liver cancer (92)
Longevity (16)
Lung cancer (666)
Lymphoma (385)
Machine learning (43)
Management (60)
Manufacturing (837)
MASH (170)
Medical device (13872)
Medtech (13928)
Mergers & acquisitions (20921)
Metabolic disorders (1313)
Multiple sclerosis (164)
NASH (17)
Neurodegenerative disease (328)
Neuropsychiatric disorders (92)
Neuroscience (2974)
Neurotech (1)
NextGen: Class of 2026 (6651)
Non-profit (4564)
Now hiring (68)
Obesity (621)
Opinion (289)
Ovarian cancer (168)
Pain (217)
Pancreatic cancer (232)
Parkinson's disease (286)
Partnered (34)
Patents (515)
Patient recruitment (502)
Peanut (60)
People (60976)
Pharmaceutical (90)
Pharmacy benefit managers (31)
Phase 1 (22109)
Phase 2 (31313)
Phase 3 (23467)
Pipeline (5491)
Policy (303)
Postmarket research (2655)
Preclinical (9393)
Press Release (68)
Prostate cancer (242)
Psychedelics (50)
Radiopharmaceuticals (290)
Rare diseases (881)
Real estate (6309)
Recruiting (72)
Regulatory (25464)
Reports (53)
Research institute (2445)
Resumes & cover letters (362)
Rett syndrome (27)
RNA editing (17)
RSV (81)
Schizophrenia (156)
Series A (247)
Series B (194)
Service/supplier (11)
Sickle cell disease (100)
Special edition (25)
Spinal muscular atrophy (160)
Sponsored (43)
Startups (3770)
State (2)
Stomach cancer (19)
Supply chain (107)
Tariffs (96)
The Weekly (78)
Vaccines (1043)
Venture capital (91)
Weight loss (406)
Women's health (94)
Worklife (18)
Date
Today (48)
Last 7 days (576)
Last 30 days (2370)
Last 365 days (30309)
2026 (4046)
2025 (30686)
2024 (35771)
2023 (40633)
2022 (51806)
2021 (56346)
2020 (54798)
2019 (47418)
2018 (35788)
2017 (33158)
2016 (32675)
2015 (38624)
2014 (32531)
2013 (27643)
2012 (29745)
2011 (30497)
2010 (28508)
Location
Africa (802)
Alabama (84)
Alaska (7)
Arizona (318)
Arkansas (14)
Asia (42190)
Australia (6758)
California (11465)
Canada (3342)
China (1143)
Colorado (483)
Connecticut (486)
Delaware (345)
Europe (90501)
Florida (1717)
Georgia (361)
Hawaii (3)
Idaho (61)
Illinois (889)
India (72)
Indiana (537)
Iowa (22)
Japan (448)
Kansas (127)
Kentucky (40)
Louisiana (26)
Maine (72)
Maryland (1404)
Massachusetts (8249)
Michigan (330)
Minnesota (635)
Mississippi (5)
Missouri (128)
Montana (32)
Nebraska (28)
Nevada (123)
New Hampshire (79)
New Jersey (3046)
New Mexico (29)
New York (3026)
North Carolina (1493)
North Dakota (8)
Northern California (5600)
Ohio (339)
Oklahoma (22)
Oregon (46)
Pennsylvania (2322)
Puerto Rico (24)
Rhode Island (48)
South America (1177)
South Carolina (68)
South Dakota (1)
Southern California (4468)
Tennessee (177)
Texas (1770)
United States (40762)
Utah (343)
Vermont (1)
Virginia (280)
Washington D.C. (81)
Washington State (937)
West Virginia (4)
Wisconsin (117)
Wyoming (2)
742,644 Results for "arena pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Alzheimer’s disease
Korsana Joins Alzheimer’s Amyloid Arena With $150M Debut, Next-Gen Antibody
Korsana’s lead program uses a next-generation shuttling technology to improve delivery into the brain and lower the incidence of amyloid-related imaging abnormalities.
February 18, 2026
·
2 min read
·
Tristan Manalac
Preclinical
Arena BioWorks Folds Less Than Two Years After Launch, Blames ‘Policy Uncertainty’
Arena launched with $500 million in early 2024 to fund basic biological research, from which it planned to spin out dedicated companies to focus on drug development.
November 5, 2025
·
2 min read
·
Tristan Manalac
Earnings
GSK Says No to GLP-1s, Prioritizes ‘Downstream Effects’ of Obesity
Instead of joining the increasingly crowded GLP-1 arena, GSK will focus its efforts downstream of obesity—a push currently anchored by its Phase III-ready FGF21 analog efimosfermin alfa for liver fibrosis.
February 4, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category
December 18, 2025
·
4 min read
Press Releases
Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer
December 18, 2025
·
4 min read
Press Releases
Science 37 Receives 2025 Clinical Trials Arena Site Innovation Award for R&D Leadership
December 3, 2025
·
2 min read
Press Releases
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
February 13, 2026
·
12 min read
Press Releases
Aucta Pharmaceuticals, Inc. (“Aucta Pharmaceuticals”) prepares for the launch of PYQUVI™ (deflazacort) oral suspension, the first of a new branded-generic rare disease product line
February 8, 2026
·
7 min read
MASH
GSK Buys Phase III–Ready Liver Drug in Potential $2B Deal To Play in MASH Arena
GSK secures rights to Boston Pharmaceuticals’ efimosfermin alfa, which the pharma plans to develop for fatty liver diseases such as metabolic dysfunction-associated steatohepatitis and alcohol-related liver disease.
May 14, 2025
·
2 min read
·
Tristan Manalac
Press Releases
60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio
January 16, 2026
·
6 min read
1 of 74,265
Next
